TMX Newsfile·2026-02-03 20:00Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Information - Tandem Diabetes Care, Inc. is facing scrutiny after a press release on August 7, 2025, announced a voluntary medical device correction for select t:slim X2 insulin pumps, which could lead to a discontinuation of insulin delivery due to a speaker-related issue [3]. - Following the announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 2: Legal Actions - Investors who purchased Tandem Diabetes securities may be eligible for compensation through a class action lawsuit being prepared by Rosen Law Firm, which operates on a contingency fee basis [2]. - The firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering substantial amounts for investors [4]. Group 3: Firm's Credentials - Rosen Law Firm has achieved notable recognition, including the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].